Calprotectin

A novel noninvasive marker for intestinal allograft monitoring

Debra Sudan, Luciano M Vargas, Yimin Sun, Lisette Bok, Gerard Dijkstra, Alan Norman Langnas

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

OBJECTIVE: To identify a noninvasive screening test for intestinal allograft monitoring. SUMMARY BACKGROUND DATA: Intestinal allograft rejection is difficult to distinguish from other causes of diarrhea and can rapidly lead to severe exfoliation or death. Protocol biopsies are standard for allograft monitoring but may cause serious complications. No noninvasive test has shown clinical utility for monitoring of the intestinal allograft. METHODS: Calprotectin levels (n = 68) were measured in this pilot study from ileostomy effluent in patients with histologic evidence of acute rejection (n = 12), viral enteritis (n = 5), and nonspecific inflammation (n = 16) and compared with those with normal allograft histology (n = 35). RESULTS: Median stool calprotectin levels from patients with rejection were significantly higher than those from patients with viral enteritis or normal biopsies [198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)]. Receiver operator characteristics suggest the optimal cut-off level to distinguish rejection from other diagnoses is 92 mg/kg with specificity of 77% and sensitivity of 83%. Although false-positive results occurred in 26% of patients with normal biopsies and 30% with nonspecific changes, no treated episode of acute rejection was below the cutoff. In addition, in 2 patients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to 18 days. CONCLUSIONS: Low stool calprotectin levels correlate well with a low risk for intestinal allograft rejection. If confirmed, biopsies may be reserved in the future for confirmation of rejection, eliminating protocol biopsies, and immunosuppressive changes could potentially be made before allograft injury.

Original languageEnglish (US)
Pages (from-to)311-315
Number of pages5
JournalAnnals of surgery
Volume246
Issue number2
DOIs
StatePublished - Aug 1 2007

Fingerprint

Leukocyte L1 Antigen Complex
Allografts
Biopsy
Enteritis
Ileostomy
Immunosuppressive Agents
Diarrhea
Histology
Inflammation
Sensitivity and Specificity
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

Calprotectin : A novel noninvasive marker for intestinal allograft monitoring. / Sudan, Debra; Vargas, Luciano M; Sun, Yimin; Bok, Lisette; Dijkstra, Gerard; Langnas, Alan Norman.

In: Annals of surgery, Vol. 246, No. 2, 01.08.2007, p. 311-315.

Research output: Contribution to journalArticle

Sudan, Debra ; Vargas, Luciano M ; Sun, Yimin ; Bok, Lisette ; Dijkstra, Gerard ; Langnas, Alan Norman. / Calprotectin : A novel noninvasive marker for intestinal allograft monitoring. In: Annals of surgery. 2007 ; Vol. 246, No. 2. pp. 311-315.
@article{c10ae6106d0c4f5e85ca657978c34d50,
title = "Calprotectin: A novel noninvasive marker for intestinal allograft monitoring",
abstract = "OBJECTIVE: To identify a noninvasive screening test for intestinal allograft monitoring. SUMMARY BACKGROUND DATA: Intestinal allograft rejection is difficult to distinguish from other causes of diarrhea and can rapidly lead to severe exfoliation or death. Protocol biopsies are standard for allograft monitoring but may cause serious complications. No noninvasive test has shown clinical utility for monitoring of the intestinal allograft. METHODS: Calprotectin levels (n = 68) were measured in this pilot study from ileostomy effluent in patients with histologic evidence of acute rejection (n = 12), viral enteritis (n = 5), and nonspecific inflammation (n = 16) and compared with those with normal allograft histology (n = 35). RESULTS: Median stool calprotectin levels from patients with rejection were significantly higher than those from patients with viral enteritis or normal biopsies [198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)]. Receiver operator characteristics suggest the optimal cut-off level to distinguish rejection from other diagnoses is 92 mg/kg with specificity of 77{\%} and sensitivity of 83{\%}. Although false-positive results occurred in 26{\%} of patients with normal biopsies and 30{\%} with nonspecific changes, no treated episode of acute rejection was below the cutoff. In addition, in 2 patients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to 18 days. CONCLUSIONS: Low stool calprotectin levels correlate well with a low risk for intestinal allograft rejection. If confirmed, biopsies may be reserved in the future for confirmation of rejection, eliminating protocol biopsies, and immunosuppressive changes could potentially be made before allograft injury.",
author = "Debra Sudan and Vargas, {Luciano M} and Yimin Sun and Lisette Bok and Gerard Dijkstra and Langnas, {Alan Norman}",
year = "2007",
month = "8",
day = "1",
doi = "10.1097/SLA.0b013e3180f61af4",
language = "English (US)",
volume = "246",
pages = "311--315",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Calprotectin

T2 - A novel noninvasive marker for intestinal allograft monitoring

AU - Sudan, Debra

AU - Vargas, Luciano M

AU - Sun, Yimin

AU - Bok, Lisette

AU - Dijkstra, Gerard

AU - Langnas, Alan Norman

PY - 2007/8/1

Y1 - 2007/8/1

N2 - OBJECTIVE: To identify a noninvasive screening test for intestinal allograft monitoring. SUMMARY BACKGROUND DATA: Intestinal allograft rejection is difficult to distinguish from other causes of diarrhea and can rapidly lead to severe exfoliation or death. Protocol biopsies are standard for allograft monitoring but may cause serious complications. No noninvasive test has shown clinical utility for monitoring of the intestinal allograft. METHODS: Calprotectin levels (n = 68) were measured in this pilot study from ileostomy effluent in patients with histologic evidence of acute rejection (n = 12), viral enteritis (n = 5), and nonspecific inflammation (n = 16) and compared with those with normal allograft histology (n = 35). RESULTS: Median stool calprotectin levels from patients with rejection were significantly higher than those from patients with viral enteritis or normal biopsies [198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)]. Receiver operator characteristics suggest the optimal cut-off level to distinguish rejection from other diagnoses is 92 mg/kg with specificity of 77% and sensitivity of 83%. Although false-positive results occurred in 26% of patients with normal biopsies and 30% with nonspecific changes, no treated episode of acute rejection was below the cutoff. In addition, in 2 patients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to 18 days. CONCLUSIONS: Low stool calprotectin levels correlate well with a low risk for intestinal allograft rejection. If confirmed, biopsies may be reserved in the future for confirmation of rejection, eliminating protocol biopsies, and immunosuppressive changes could potentially be made before allograft injury.

AB - OBJECTIVE: To identify a noninvasive screening test for intestinal allograft monitoring. SUMMARY BACKGROUND DATA: Intestinal allograft rejection is difficult to distinguish from other causes of diarrhea and can rapidly lead to severe exfoliation or death. Protocol biopsies are standard for allograft monitoring but may cause serious complications. No noninvasive test has shown clinical utility for monitoring of the intestinal allograft. METHODS: Calprotectin levels (n = 68) were measured in this pilot study from ileostomy effluent in patients with histologic evidence of acute rejection (n = 12), viral enteritis (n = 5), and nonspecific inflammation (n = 16) and compared with those with normal allograft histology (n = 35). RESULTS: Median stool calprotectin levels from patients with rejection were significantly higher than those from patients with viral enteritis or normal biopsies [198 mg/kg compared with 7 and 19 mg/kg, respectively (P = 0.0002)]. Receiver operator characteristics suggest the optimal cut-off level to distinguish rejection from other diagnoses is 92 mg/kg with specificity of 77% and sensitivity of 83%. Although false-positive results occurred in 26% of patients with normal biopsies and 30% with nonspecific changes, no treated episode of acute rejection was below the cutoff. In addition, in 2 patients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to 18 days. CONCLUSIONS: Low stool calprotectin levels correlate well with a low risk for intestinal allograft rejection. If confirmed, biopsies may be reserved in the future for confirmation of rejection, eliminating protocol biopsies, and immunosuppressive changes could potentially be made before allograft injury.

UR - http://www.scopus.com/inward/record.url?scp=34547591860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547591860&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e3180f61af4

DO - 10.1097/SLA.0b013e3180f61af4

M3 - Article

VL - 246

SP - 311

EP - 315

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -